DUN61488
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206933

CAS#: 1807861-48-8

Description: DUN61488, also known as 2,4,6,7,8,9-Hexahydro-7-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]methyl]imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one is a chemical reagent for research use. It has CAS#1807861-48-8. According to MedKoo Chemical Nomenclature ((see web page: https://www.medkoo.com/page/naming)., this chemical can be named as DUN61488.


Chemical Structure

img
DUN61488
CAS# 1807861-48-8

Theoretical Analysis

MedKoo Cat#: 206933
Name: DUN61488
CAS#: 1807861-48-8
Chemical Formula: C24H23F3N4O
Exact Mass: 440.1824
Molecular Weight: 440.4702
Elemental Analysis: C, 65.44; H, 5.26; F, 12.94; N, 12.72; O, 3.63

Price and Availability

Size Price Availability Quantity
10.0mg USD 150.0 Ready to ship
25.0mg USD 250.0 Ready to ship
50.0mg USD 450.0 Ready to ship
100.0mg USD 750.0 Ready to ship
200.0mg USD 1350.0 Ready to ship
Bulk inquiry

Related CAS #: 1807861-48-8    

Synonym: DUN61488; DUN-61488; DUN 61488;

IUPAC/Chemical Name: 2,4,6,7,8,9-Hexahydro-7-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]methyl]imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one

InChi Key: DFULPGUTXZTYKA-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H23F3N4O/c25-24(26,27)19-8-6-18(7-9-19)15-31-22(32)20-16-29(14-17-4-2-1-3-5-17)12-10-21(20)30-13-11-28-23(30)31/h1-9H,10-16H2

SMILES Code: O=C1N(CC2=CC=C(C(F)(F)F)C=C2)C3=NCCN3C4=C1CN(CC5=CC=CC=C5)CC4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer agent and also a selective agonist of GPR132.
In vitro activity: ONC‐212 induced a significant (P < .05) accumulation of cells from both the OSU‐CLL and OSU‐CLL‐TP53ko lines in G0/G1, with a concomitant decrease in the proportion of cells in G2/M at each of the three time points (P < .05; Figure 2A). In the TP53ko cells, a significant (P < .05) increase in the proportion of cells in S phase was also observed with ONC‐212 treatment at each time point. Reference: EJHaem. 2021 Jan 14;2(1):81-93. https://pubmed.ncbi.nlm.nih.gov/35846080/
In vivo activity: Immunohistochemical analyses of Ki67 and caspase-3 demonstrated that ONC212 reduced tumor-cell proliferation and induced apoptosis in UACC-903 and MALME xenografts to a greater extent than ONC201 (Fig. 7d, Fig. S4c). Reference: Cell Cycle. 2017 Oct 2;16(19):1790-1799. https://pubmed.ncbi.nlm.nih.gov/28489985/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 1.0 2.27
DMSO 25.5 57.89
DMSO:PBS (pH 7.2) (1:3) 0.25 0.57

Preparing Stock Solutions

The following data is based on the product molecular weight 440.4702 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Ferrarini I, Louie A, Zhou L, El-Deiry WS. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Mol Cancer Ther. 2021 Sep;20(9):1572-1583. doi: 10.1158/1535-7163.MCT-20-0962. Epub 2021 Jun 17. PMID: 34224362; PMCID: PMC8419089. 2. Fatima N, Shen Y, Crassini K, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. EJHaem. 2021 Jan 14;2(1):81-93. doi: 10.1002/jha2.160. PMID: 35846080; PMCID: PMC9175891. 3. Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10. PMID: 28489985; PMCID: PMC5628644. 4. Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. PMID: 29137221; PMCID: PMC5669847.
In vitro protocol: 1. Ferrarini I, Louie A, Zhou L, El-Deiry WS. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Mol Cancer Ther. 2021 Sep;20(9):1572-1583. doi: 10.1158/1535-7163.MCT-20-0962. Epub 2021 Jun 17. PMID: 34224362; PMCID: PMC8419089. 2. Fatima N, Shen Y, Crassini K, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. EJHaem. 2021 Jan 14;2(1):81-93. doi: 10.1002/jha2.160. PMID: 35846080; PMCID: PMC9175891.
In vivo protocol: 1. Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10. PMID: 28489985; PMCID: PMC5628644. 2. Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. PMID: 29137221; PMCID: PMC5669847.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

DUN61488

10.0mg / USD 150.0